Clinical Trials
Saint Luke's Cancer Institute has the region's largest portfolio of clinical trials for Stage 4 breast cancer, and access to more than 200 National Cancer Institute (NCI) clinical trials and industry-sponsored trials.
Clinical trials help physicians and researchers find better ways to prevent, diagnose, and treat cancer. For many patients, participation in a clinical trial improves outcomes and quality of life.
Currently Enrolling
The Koontz Center is currently enrolling patients in the following trials specifically targeting advanced breast cancer.
A Phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2 antibody drug conjugate (ADC) versus treatment of physician's choice for HER2 low, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303). Learn more about this trial (NCT03734029)
A Phase II, Open Label, Randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE). Learn more about this trial (NCT03330847)
A Phase 2 study of SAR439859 vs physician's choice in premenopausal and postmenopausal localled advanced or metastatic ER-positive breast cancer. Learn more about this trial (NCT04059484)
A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer(OPERA). Learn more about this trial (NCT03326102)
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated with Prior Standard of Care HER2 Therapies, Including T DM1. Learn more about this trial (NCT03523585)
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Fulvestrant in Subjects With ER+ Breast Cancer. Learn more about this trial (NCT02964507)
A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified But HER2 Mutant Breast Cancer. Learn more about this trial (NCT01670877)
A Phase III study of Sacituzumab Govitecan (IMMU-132) versus treatment of physician’s Choice in HR+ Her2 negative metastatic breast cancer patients who have failed at least two prior lines of chemotherapy. Learn more about this trial (NCT03901339)
A Phase 3 study of eribulin with or without a C-X-C Chemokine Receptor Type 4 (CXCR4) antagonist in patients with human epidermal growth factor receptor (HER2) negative, locally recurrent and metastatic breast cancer (BC) that has relapsed after prior therapy. Learn more about this trial (NCT03786094)
A Phase 3 clinical trial of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer. Learn more about this trial (NCT03975647)